Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline

Priya Patel; Paula D. Robinson; Marie Cohen; Katie Devine; Paul Gibson; Mark T. Holdsworth; Eloise Neumann; Andrea Orsey; Robert Phillips; Daniela Spinelli; Jennifer Thackray; Marianne van de Wetering; Deborah Woods; Sandra Cabral; Lillian Sung; L. Lee Dupuis

doi:10.1002/pbc.30001

Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline

Priya Patel, Paula D. Robinson, Marie Cohen, Katie Devine, Paul Gibson, Mark T. Holdsworth, Eloise Neumann, Andrea Orsey, Robert Phillips, Daniela Spinelli, Jennifer Thackray, Marianne van de Wetering, Deborah Woods, Sandra Cabral, Lillian Sung, L. Lee Dupuis

Research related

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

Abstract

This clinical practice guideline provides recommendations for preventing acute and delayed phase chemotherapy-induced nausea and vomiting (CINV) in pediatric patients. The recommendations are based on two systematic reviews of randomized controlled trials evaluating interventions to prevent (1) acute phase CINV and (2) delayed phase CINV. Recommendations for acute phase and delayed phase CINV prophylaxis are made for patients receiving chemotherapy of varying emetogenicity, as well as for patients not able to receive dexamethasone or a neurokinin-1 receptor antagonist. Evidence gaps, including antiemetic safety and optimal dosing, were identified.

Original language	English
Article number	e30001
Pages (from-to)	e30001
Journal	Pediatric Blood and Cancer
Volume	69
Issue number	12
DOIs	https://doi.org/10.1002/pbc.30001
Publication status	Published - Dec 2022

Keywords

chemotherapy-induced nausea and vomiting
guideline
pediatric oncology
supportive care
Nausea/chemically induced
Humans
Neoplasms/drug therapy
Randomized Controlled Trials as Topic
Vomiting/chemically induced
Systematic Reviews as Topic
Antineoplastic Agents/adverse effects
Child
Antiemetics/therapeutic use

Access to Document

10.1002/pbc.30001

Cite this

Patel, P., Robinson, P. D., Cohen, M., Devine, K., Gibson, P., Holdsworth, M. T., Neumann, E., Orsey, A., Phillips, R., Spinelli, D., Thackray, J., van de Wetering, M., Woods, D., Cabral, S., Sung, L., & Dupuis, L. L. (2022). Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline. Pediatric Blood and Cancer, 69(12), e30001. Article e30001. https://doi.org/10.1002/pbc.30001

@article{506f3247f82e4c3e9a381a3d9b532ce4,

title = "Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline",

abstract = "This clinical practice guideline provides recommendations for preventing acute and delayed phase chemotherapy-induced nausea and vomiting (CINV) in pediatric patients. The recommendations are based on two systematic reviews of randomized controlled trials evaluating interventions to prevent (1) acute phase CINV and (2) delayed phase CINV. Recommendations for acute phase and delayed phase CINV prophylaxis are made for patients receiving chemotherapy of varying emetogenicity, as well as for patients not able to receive dexamethasone or a neurokinin-1 receptor antagonist. Evidence gaps, including antiemetic safety and optimal dosing, were identified.",

keywords = "chemotherapy-induced nausea and vomiting, guideline, pediatric oncology, supportive care, Nausea/chemically induced, Humans, Neoplasms/drug therapy, Randomized Controlled Trials as Topic, Vomiting/chemically induced, Systematic Reviews as Topic, Antineoplastic Agents/adverse effects, Child, Antiemetics/therapeutic use",

author = "Priya Patel and Robinson, {Paula D.} and Marie Cohen and Katie Devine and Paul Gibson and Holdsworth, {Mark T.} and Eloise Neumann and Andrea Orsey and Robert Phillips and Daniela Spinelli and Jennifer Thackray and {van de Wetering}, Marianne and Deborah Woods and Sandra Cabral and Lillian Sung and Dupuis, {L. Lee}",

note = "{\textcopyright} 2022 Wiley Periodicals LLC.",

year = "2022",

month = dec,

doi = "10.1002/pbc.30001",

language = "English",

volume = "69",

pages = "e30001",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "12",

}

Patel, P, Robinson, PD, Cohen, M, Devine, K, Gibson, P, Holdsworth, MT, Neumann, E, Orsey, A, Phillips, R, Spinelli, D, Thackray, J, van de Wetering, M, Woods, D, Cabral, S, Sung, L & Dupuis, LL 2022, 'Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline', Pediatric Blood and Cancer, vol. 69, no. 12, e30001, pp. e30001. https://doi.org/10.1002/pbc.30001

TY - JOUR

T1 - Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients

T2 - A clinical practice guideline

AU - Patel, Priya

AU - Robinson, Paula D.

AU - Cohen, Marie

AU - Devine, Katie

AU - Gibson, Paul

AU - Holdsworth, Mark T.

AU - Neumann, Eloise

AU - Orsey, Andrea

AU - Phillips, Robert

AU - Spinelli, Daniela

AU - Thackray, Jennifer

AU - van de Wetering, Marianne

AU - Woods, Deborah

AU - Cabral, Sandra

AU - Sung, Lillian

AU - Dupuis, L. Lee

PY - 2022/12

Y1 - 2022/12

N2 - This clinical practice guideline provides recommendations for preventing acute and delayed phase chemotherapy-induced nausea and vomiting (CINV) in pediatric patients. The recommendations are based on two systematic reviews of randomized controlled trials evaluating interventions to prevent (1) acute phase CINV and (2) delayed phase CINV. Recommendations for acute phase and delayed phase CINV prophylaxis are made for patients receiving chemotherapy of varying emetogenicity, as well as for patients not able to receive dexamethasone or a neurokinin-1 receptor antagonist. Evidence gaps, including antiemetic safety and optimal dosing, were identified.

AB - This clinical practice guideline provides recommendations for preventing acute and delayed phase chemotherapy-induced nausea and vomiting (CINV) in pediatric patients. The recommendations are based on two systematic reviews of randomized controlled trials evaluating interventions to prevent (1) acute phase CINV and (2) delayed phase CINV. Recommendations for acute phase and delayed phase CINV prophylaxis are made for patients receiving chemotherapy of varying emetogenicity, as well as for patients not able to receive dexamethasone or a neurokinin-1 receptor antagonist. Evidence gaps, including antiemetic safety and optimal dosing, were identified.

KW - chemotherapy-induced nausea and vomiting

KW - guideline

KW - pediatric oncology

KW - supportive care

KW - Nausea/chemically induced

KW - Humans

KW - Neoplasms/drug therapy

KW - Randomized Controlled Trials as Topic

KW - Vomiting/chemically induced

KW - Systematic Reviews as Topic

KW - Antineoplastic Agents/adverse effects

KW - Child

KW - Antiemetics/therapeutic use

UR - http://www.scopus.com/inward/record.url?scp=85140074410&partnerID=8YFLogxK

U2 - 10.1002/pbc.30001

DO - 10.1002/pbc.30001

M3 - Article

C2 - 36221901

AN - SCOPUS:85140074410

SN - 1545-5009

VL - 69

SP - e30001

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 12

M1 - e30001

ER -

Prevention of acute and delayed chemotherapy-induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline

Abstract

Keywords

Access to Document

Fingerprint

Cite this